R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia

被引：14
|
作者：
Tonino, S. H. [1 ,2 ]
van Gelder, M. [3 ]
Eldering, E. [2 ]
van Oers, M. H. [1 ]
Kater, A. P. [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Hematol, Maastricht, Netherlands
来源：
LEUKEMIA | 2010年 / 24卷 / 03期
关键词：
OXALIPLATIN;
D O I：
10.1038/leu.2009.240
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：652 / 654
页数：4
相关论文
共 50 条
  • [1] R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia
    S H Tonino
    M van Gelder
    E Eldering
    M H van Oers
    A P Kater
    Leukemia, 2010, 24 : 652 - 654
  • [2] Treatment of Fludarabine-refractory Chronic Lymphocytic Leukemia
    Tsimberidou, Apostolia-Maria
    Keating, Michael J.
    CANCER, 2009, 115 (13) : 2824 - 2836
  • [3] R-DHAP Is Effective in Fludarabine-Refractory CLL, Possibly Via Upregulation of Pro-Apoptotic P73.
    Tonino, Sanne H.
    Van Gelder, Michel
    Eldering, Eric
    van Oers, Marinus H. J.
    Kater, Arnon P.
    BLOOD, 2009, 114 (22) : 1340 - 1340
  • [4] Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia
    Gritti, Giuseppe
    Reda, Gianluigi
    Maura, Francesco
    Piciocchi, Alfonso
    Baldini, Luca
    Molica, Stefano
    Neri, Antonino
    Cortelezzi, Agostino
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 424 - 429
  • [5] Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study
    Malik, Asifa
    Shoulder, Mahran
    Garcia-Manero, Guillermo
    Wierda, William
    Cortes, Jorge
    Bickel, Susan
    Keating, Michael J.
    Estrov, Zeev
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03): : 292 - 295
  • [6] Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients.
    Chanan-Khan, AsherA.
    Czuczman, Myron S.
    Padmanabhan, Swarminathan
    Keating, Michael J.
    O'Brien, Susan M.
    Wierda, William G.
    Ferrajoli, Alessandra
    BLOOD, 2007, 110 (11) : 914A - 914A
  • [7] Economic Analysis of Alemtuzumab in Fludarabine-Refractory and Relapsed Chronic Lymphocytic Leukemia in Canada
    Isogai, Pierre K.
    Cheung, Matthew
    Mittmann, Nicole
    BLOOD, 2008, 112 (11) : 827 - 827
  • [8] Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options
    Tsimberidou, Apostolia-Maria
    Keating, Michael J.
    LEUKEMIA & LYMPHOMA, 2010, 51 (07) : 1188 - 1199
  • [9] Phase II Trial of Subcutaneous Alemtuzumab in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 202 - 203
  • [10] What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
    Byrd, JC
    Rai, KR
    SEMINARS IN ONCOLOGY, 2000, 27 (04) : XII - XIII
12345